PMV Pharmaceuticals, Inc. (PMVP)
| Market Cap | 67.20M -16.6% |
| Revenue (ttm) | n/a |
| Net Income | -75.22M |
| EPS | -1.41 |
| Shares Out | 53.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,816 |
| Open | 1.230 |
| Previous Close | 1.215 |
| Day's Range | 1.215 - 1.285 |
| 52-Week Range | 1.020 - 1.880 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+217.46%) |
| Earnings Date | Aug 14, 2026 |
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PMVP stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 217.46% from the latest price.
News
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals Quarterly report: Q2 2026
PMV Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
PMV Pharmaceuticals Earnings release: Q2 2026
PMV Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
PMV Pharmaceuticals assumed with a Buy at Ladenburg
Ladenburg assumed coverage of PMV Pharmaceuticals (PMVP) with a Buy rating and $3 price target PMV is developing rezatapopt, a precision drug for the treatment of solid tumors, the analyst…
PMV Pharmaceuticals Transcript: AGM 2026
The meeting featured the election of two directors, approval of executive compensation, and auditor ratification. No shareholder questions were raised, and all proposals passed as recommended by the board.
PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer
Oppenheimer lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $5 from $6 and keeps an Outperform rating on the shares following quarterly results and business update. Rezatapopt continu...
PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)
“The first quarter was one of continued execution as we advance the PYNNACLE study and remain on track to target an NDA submission for rezatapopt for platinum-resistant/refractory ovarian cancer in…
PMV Pharmaceuticals Quarterly report: Q1 2026
PMV Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
PMV Pharmaceuticals Earnings release: Q1 2026
PMV Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed
PMV Pharmaceuticals (PMVP) announced a transition on its board of directors. Laurie Stelzer, who has served as a member of the board since 2020, has been appointed chair of the…
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director...
PMV Pharmaceuticals Proxy statement: Proxy filing
PMV Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
PMV Pharmaceuticals Proxy statement: Proxy filing
PMV Pharmaceuticals filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI
Evercore ISI lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $4 from $16 and keeps an Outperform rating on the shares. The firm updated models among its small-to-mid…
PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
“2025 was an important and productive year for PMV Pharma as we reported positive Phase 2 interim data from the registrational PYNNACLE clinical trial and made significant progress in enrolling…
PMV Pharmaceuticals sees cash runway to end of 2Q27
As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, compared to $183.3 million at December 31, 2024. Net cash used in operations…
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm...
PMV Pharmaceuticals Earnings release: Q4 2025
PMV Pharmaceuticals released its Q4 2025 earnings on March 6, 2026, summarizing the period's financial results.
PMV Pharmaceuticals Annual report: Q4 2025
PMV Pharmaceuticals has published its Q4 2025 annual report on March 6, 2026.
PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Rezatapopt demonstrates strong efficacy and safety in heavily pretreated ovarian cancer, with a 46% ORR and 8-month median DOR. NDA submission is planned for Q1 2027, with global expansion and combination studies underway. US market potential is estimated at $350–$420 million.
PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM
PMV Pharmaceuticals (PMVP) announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harborin...
PMV Pharmaceuticals Slides: Corporate presentation
PMV Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on February 5, 2026.
PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)
“I am incredibly proud of our team and their commitment to rapidly and efficiently advancing the PYNNACLE study,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.
PMV Pharmaceuticals Earnings release: Q3 2025
PMV Pharmaceuticals released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
PMV Pharmaceuticals Quarterly report: Q3 2025
PMV Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 12, 2025.